INSULET CORP

Lisa Blair’s recent sale of 244 Insulet shares is a routine tax‑withholding move, reflecting steady insider confidence and a long‑term hold on insulin‑infusion tech.

Insulet insider buys 1,355 RSUs as board signals confidence amid volatile market; learn what this move means for investors and future growth.

Insulet insider buys 2,790 shares at $143.51, showing confidence amid a steep decline to a 52‑week low. Learn why this modest purchase may signal a rebound.

Insulet Corp insider buy: Elizabeth Weatherman’s 3,450‑share purchase hints at management confidence amid a steep decline, signaling potential rebound and long‑term upside.

Insulet insider buying shows executive confidence: EVP Panos Michael’s April 2026 purchase signals optimism amid a 16.8% monthly decline, hinting at future upside despite high P/E and regulatory risks.

Insulet CEO Ashley McEvoy buys 4,300 shares, signaling confidence as the company expands its insulin platform and seeks growth in Canada and the UK.

Insulet insider trades show routine vesting, not volatility—executives buy and sell shares near current price, signaling confidence and steady growth prospects.